Pharmacotherapy
Phase 3Small molecule
Pharmacotherapy is one of 194 small molecule programs targeting Chronic Pelvic Pain. It is currently in Phase 3.
8
Indications
15
Total Trials
3
Active Trials
193
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
100 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Dayvigo
EisaiApproved
Lexapro
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Azilect
TevaApproved
Neupro
UCBApproved
Evista
Eli LillyApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Kisunla
Eli LillyPhase 3
Accutane
CConrado Roberto Hoffmann Filho
Approved
Ulotaront
IIntra-Cellular Therapies, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Coronary Artery Bypass1 trial
10 more indications
Allergic Rhinitis1 trial
Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children
Completed·—·N/A·NCT01291381·50 enrolled
Chronic Pelvic Pain1 trial
Alzheimer disease1 trial
Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease
Completed·—·N/A·NCT04754152·45 enrolled
Bruxism1 trial
A Comparative Study of EMG Biofeedback and Pharmacotherapy for the Treatment of Masticatory Muscle Hyperactivity in Bruxism Patients
Not yet recruiting·—·N/A·NCT06894472·30 enrolled
Endothelial Dysfunction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pharmacotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pittsburgh